Anna Protopapas to lead Takeda’s global business development unit
pharmafile | October 21, 2010 | Appointment | Sales and Marketing | Anna Protopapas, Japanese pharma company, Takeda, appointment, sales and marketing
Takeda has set up a new global business development unit within its US subsidiary to oversee mergers, acquisitions and other development functions across the world.
It will be by Anna Protopapas, who was previously in charge of business development for the Japanese pharma company’s oncology company Millennium.
“As set forth in the FY10-12 Mid-Range Plan, Takeda is committed to making strategic investments both actively and flexibly in business development, while ensuring the maximum potential of each project and return from such investments” said Yasuchika Hasegawa, president and chief executive of Takeda.
“I believe that the establishment of the Global Business Development organisation and the appointment of Ms Anna Protopapas as its leader will enable us to achieve this important initiative with even greater momentum and speed.”
The new unit will manage business development related activities, such as mergers and acquisitions, product purchases, and in-and out-licensing of the R&D pipeline, prioritising global opportunities that arise.
Related Content

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …






